Acknowledgement
Supported by : National Research Foundation of Korea (NRF), Korea University Anam Hospital
References
- Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008). https://doi.org/10.1038/nature06914
- Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015). https://doi.org/10.3322/caac.21262
- Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012). https://doi.org/10.1016/S0140-6736(11)61347-0
- Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7-30 (2017). https://doi.org/10.3322/caac.21387
- El-Serag, H. B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34 (2004). https://doi.org/10.1053/j.gastro.2004.09.013
- Shaw, J. J. & Shah, S. A. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev. Gastroenterol. Hepatol. 5, 365-370 (2011). https://doi.org/10.1586/egh.11.20
- Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008). https://doi.org/10.3322/CA.2007.0010
- Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56-66 (2017). https://doi.org/10.1016/S0140-6736(16)32453-9
- Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008). https://doi.org/10.1056/NEJMoa0708857
- Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43, 464-469 (2011). https://doi.org/10.1038/ng.804
- Guichard, C. et al. Integrated analysis of somatic mutations and focal copynumber changes identifies. Nat. Genet. 44, 694-698 (2012). https://doi.org/10.1038/ng.2256
- Huang, J. et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 44, 1117-1121 (2012). https://doi.org/10.1038/ng.2391
- Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58, 1693-1702 (2013). https://doi.org/10.1002/hep.26540
- Fujimoto, A. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500-509 (2016). https://doi.org/10.1038/ng.3547
- Lee, J. S. The mutational landscape of hepatocellular carcinoma. Clin. Mol. Hepatol. 21, 220-229 (2015). https://doi.org/10.3350/cmh.2015.21.3.220
- Lee, J. S. Exploring cancer genomic data from the cancer genome atlas project. BMB Rep. 49, 607-611 (2016). https://doi.org/10.5483/BMBRep.2016.49.11.145
- Consortium, T. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327-1341 (2017). https://doi.org/10.1016/j.cell.2017.05.046
- Schonfeld, G. Familial hypobetalipoproteinemia: a review. J. Lipid Res. 44, 878-883 (2003). https://doi.org/10.1194/jlr.R300002-JLR200
- Lonardo, A., Tarugi, P., Ballarini, G. & Bagni, A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy. Dig. Dis. Sci. 43, 2489-2492 (1998). https://doi.org/10.1023/A:1026646618643
- Lee, J. S. et al. Application of comparative functional genomics to identify bestfit mouse models to study human cancer. Nat. Genet. 36, 1306-1311 (2004). https://doi.org/10.1038/ng1481
- Lee, J. S. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410-416 (2006). https://doi.org/10.1038/nm1377
- Park, Y. Y. et al. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology 63, 159-172 (2016). https://doi.org/10.1002/hep.28223
- Tadin-Strapps, M. et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model. J. Lipid Res. 52, 1084-1097 (2011). https://doi.org/10.1194/jlr.M012872
- Dong, B. et al. Activating CAR and beta-catenin induces uncontrolled liver growth and. Nat. Commun. 6, 5944 (2015). https://doi.org/10.1038/ncomms6944
- Lim, H. Y. et al. Prediction of disease-free survival in hepatocellular carcinoma by gene. Ann. Surg. Oncol. 20, 3747-3753 (2013). https://doi.org/10.1245/s10434-013-3070-y
- Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in. Cancer Res. 70, 10202-10212 (2010). https://doi.org/10.1158/0008-5472.CAN-10-2607
- Roessler, S. et al. Integrative genomic identification of genes on 8p associated with hepatocellular. Gastroenterology 142, 957-966 (2012). https://doi.org/10.1053/j.gastro.2011.12.039
- Lee, J. S. et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40, 667-676 (2004). https://doi.org/10.1002/hep.20375
- Thorgeirsson, S. S., Lee, J. S. & Grisham, J. W. Functional genomics of hepatocellular carcinoma. Hepatology 43, S145-S150 (2006). https://doi.org/10.1002/hep.21063
- Woo, H. G. et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 14, 2056-2064 (2008). https://doi.org/10.1158/1078-0432.CCR-07-1473
- Kim, S. M. et al. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55, 1443-1452 (2012). https://doi.org/10.1002/hep.24813
- Kim, J. H. et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 11, e1001770 (2014). https://doi.org/10.1371/journal.pmed.1001770
- Sohn, B. H. et al. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin. Cancer Res. 22, 1256-1264 (2016). https://doi.org/10.1158/1078-0432.CCR-15-1447
- Oh, S. C. et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat. Commun. 9, 1777 (2018). https://doi.org/10.1038/s41467-018-04179-8
- Simon, R. et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 3, 11-17 (2007).
- Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998). https://doi.org/10.1073/pnas.95.25.14863
- Kaposi-Novak, P. et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595 (2006). https://doi.org/10.1172/JCI27236
- Ahn, S. M. et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972-1982 (2014). https://doi.org/10.1002/hep.27198
- Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on. Nat. Genet. 44, 760-764 (2012). https://doi.org/10.1038/ng.2291
- Cefalu, A. B. et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 2021-2025 (2013). https://doi.org/10.1161/ATVBAHA.112.301101
- Welty, F. K. Hypobetalipoproteinemia and abetalipoproteinemia. Curr. Opin. Lipidol. 25, 161-168 (2014). https://doi.org/10.1097/MOL.0000000000000072
- Tarugi, P. & Lonardo, A. Heterozygous familial hypobetalipoproteinemia associated with fatty liver. Am. J. Gastroenterol. 92, 1400-1402 (1997).
- Bonnefont-Rousselot, D. et al. Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur. J. Gastroenterol. Hepatol. 21, 104-108 (2009). https://doi.org/10.1097/MEG.0b013e3282ffd9f8
- Lonardo, A., Tarugi, P., Ballarini, G. & Bagni, A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig. Dis. Sci. 43, 2489-2492 (1998). https://doi.org/10.1023/A:1026646618643
- Hegele, R. A. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10, 109-121 (2009).
- Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl. Acad. Sci. USA 101, 2082-2087 (2004). https://doi.org/10.1073/pnas.0308617100
- Watanabe, S., Horie, Y. & Suzuki, A. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 33, 161-166 (2005). https://doi.org/10.1016/j.hepres.2005.09.026
- Wang, L. et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37, 389-396 (2007). https://doi.org/10.1111/j.1872-034X.2007.00042.x
- Whittaker, S., Marais, R. & Zhu, A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010). https://doi.org/10.1038/onc.2010.236
- Wu, S. K. et al. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent. World J. Gastroenterol. 13, 4554-4559 (2007). https://doi.org/10.3748/wjg.v13.i34.4554
- Qiu, W. et al. Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. Hepatology 48, 1799-1809 (2008). https://doi.org/10.1002/hep.22565
- Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating. Nat. Rev. Drug Discov. 5, 835-844 (2006). https://doi.org/10.1038/nrd2130
- Wang, F. B., Zhu, C. L., Liu, X. & Gao, G. S. HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis. 10, 207 (2011). https://doi.org/10.1186/1476-511X-10-207
Cited by
- Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease vol.9, pp.None, 2019, https://doi.org/10.1038/s41598-019-39998-2
- Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma vol.12, pp.None, 2018, https://doi.org/10.2147/ott.s192631
- Characterization of Lipid and Lipid Droplet Metabolism in Human HCC vol.8, pp.5, 2018, https://doi.org/10.3390/cells8050512
- Apolipoproteins and cancer vol.8, pp.16, 2018, https://doi.org/10.1002/cam4.2587
- Low Expression of APOB mRNA or Its Hypermethylation Predicts Favorable Overall Survival in Patients with Low-Grade Glioma vol.13, pp.None, 2018, https://doi.org/10.2147/ott.s257794
- ApoB/ApoA-1 Ratio as a Novel Prognostic Predictor in Patients With Primary Small Cell Carcinoma of the Esophagus vol.10, pp.None, 2018, https://doi.org/10.3389/fonc.2020.00610
- Exploring Metabolic Consequences of CPS1 and CAD Dysregulation in Hepatocellular Carcinoma by Network Reconstruction vol.7, pp.None, 2020, https://doi.org/10.2147/jhc.s239039
- LINC02499, a novel liver‐specific long non‐coding RNA with potential diagnostic and prognostic value, inhibits hepatocellular carcinoma cell proliferation, migration, and invasion vol.50, pp.6, 2018, https://doi.org/10.1111/hepr.13491
- Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases vol.10, pp.None, 2018, https://doi.org/10.1038/s41598-020-61298-3
- Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC vol.22, pp.8, 2018, https://doi.org/10.3390/ijms22084173
- The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma vol.13, pp.15, 2018, https://doi.org/10.3390/cancers13153740
- The Emerging Role of Stress Granules in Hepatocellular Carcinoma vol.22, pp.17, 2018, https://doi.org/10.3390/ijms22179428